Pinealon (Glu-Asp-Pro): Peptide Bioregulation of Neural Gene Expression and Neuroprotection

Overview

Pinealon is a short peptide bioregulator (glutamic acid–aspartic acid–proline; Glu-Asp-Pro) developed within the framework of peptide bioregulation research, notably by Khavinson and colleagues. It is one of a class of short peptides hypothesized to interact with DNA promoter elements to selectively modulate gene expression, particularly in neural tissue.

Mechanism of Action

Pinealon has been reported to interact with DNA promoter regions containing complementary nucleotide motifs, potentially influencing the transcription of genes involved in neuronal survival, antioxidant defense, and circadian regulation. Notable targets include the BMAL1/Clock circadian gene complex and the Bcl-2 anti-apoptotic pathway. The peptide is understood to cross the blood-brain barrier, with intranasal delivery under investigation for enhanced CNS bioavailability.

Preclinical Evidence

Neuroprotection and Cognitive Aging

In vivo studies in aged rodent models have reported that Pinealon administration is associated with improved performance in behavioral cognitive tasks, reduction in oxidative stress markers in brain tissue, and upregulation of neuroprotective gene expression. These findings are consistent with a neuroprotective profile relevant to age-related cognitive decline.

Ischemic and Oxidative Stress Models

Animal models of cerebral ischemia and oxidative stress have been used to evaluate Pinealon's neuroprotective potential, with reported reductions in neuronal apoptosis and infarct volume in treated groups. These effects are attributed to modulation of the Bcl-2/Bax apoptotic balance and attenuation of reactive oxygen species.

Circadian Modulation

Pinealon has been reported to influence circadian gene expression (BMAL1, Clock), suggesting a potential role in normalizing age-related disruption of circadian rhythms, which is increasingly recognized as a contributor to neurodegeneration.

Evidence Assessment

Pinealon is supported by in vivo animal model evidence demonstrating neuroprotective, cognitive, and antioxidant effects. No large-scale human clinical trials have been published in indexed Western databases to date. The evidence tier is preclinical, and the mechanism, while biologically plausible, would benefit from further independent validation.